- Previous Close
0.7972 - Open
0.8600 - Bid 0.6160 x 200
- Ask 1.0700 x 200
- Day's Range
0.8279 - 0.8901 - 52 Week Range
0.7150 - 6.1650 - Volume
1,550,244 - Avg. Volume
1,646,747 - Market Cap (intraday)
4.56M - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-8.0300 - Earnings Date Mar 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
www.dermatarx.comRecent News: DRMA
View More
Performance Overview: DRMA
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DRMA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DRMA
View MoreValuation Measures
Market Cap
4.40M
Enterprise Value
1.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.82
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-135.87%
Return on Equity (ttm)
-310.44%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.29M
Diluted EPS (ttm)
-8.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
3.16M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.65M